Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.

Sponsor
West Virginia University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01880112
Collaborator
(none)
0
1
2
24
0

Study Details

Study Description

Brief Summary

Patients undergoing Cesarean delivery (C-Section) with a body mass index of 30 or less will be given either 2 grams or 4 grams of an antibiotic before surgery. The antibiotic is intended to prevent infection from the surgery. It is unknown what the best dose for the usual medicine used for this purpose (an antibiotic medicine called cefazolin). Samples of the tissue just under the skin will be biopsied at the time the incision is made and at the time the cut is stitched or stapled closed. A sample of the muscle of the womb will be taken as the womb is stitched closed after the delivery. Blood tests will be done at the start and end of surgery to test the antibiotic level. A blood sample will be taken from the umbilical cord after the baby has been delivered and the umbilical cord has been cut. The umbilical cord blood sample will be tested for the antibiotic level. These tests will be used to find out if the usual dose of medicine is enough or if more medicine is needed to prevent infection in normal weight women undergoing c-sections.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.
Study Start Date :
Jun 1, 2011
Actual Primary Completion Date :
Jun 1, 2013
Anticipated Study Completion Date :
Jun 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: 4 gram dose

Pre-operative prophylactic dose of 4 grams of cefazolin

Drug: Cefazolin
Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
Other Names:
  • Ancef
  • Active Comparator: 2 gram dose

    Pre-operative prophylactic dose of 2 grams of cefazolin

    Drug: Cefazolin
    Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
    Other Names:
  • Ancef
  • Outcome Measures

    Primary Outcome Measures

    1. Cefazolin drug level. [Tissue and blood samples will be drawn during the surgical case only. Duration expected to be less than 120 minutes.]

      Measurement of the serum and tissue level of cefazolin.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 18 years or above

    2. Body mass index (BMI) of 30 or less, as calculated from the height and weight at the first prenatal visit

    3. Undergoing cesarean delivery

    Exclusion Criteria:
    1. BMI greater than 30.

    2. Not undergoing Cesarean delivery.

    3. Age less than 18 years.

    4. Pre-existing infection.

    5. Allergy to cephalosporin medications or a history of an anaphylactic reaction to penicillin.

    6. Cesarean delivery being performed under emergent circumstances

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 West Virginia University Hospital Morgantown West Virginia United States 26506

    Sponsors and Collaborators

    • West Virginia University

    Investigators

    • Principal Investigator: William H Holls, MD, West Virginia University
    • Study Chair: Michael L Stitely, MD, West Virginia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Stitely, Adjunct Associate Professor, West Virginia University
    ClinicalTrials.gov Identifier:
    NCT01880112
    Other Study ID Numbers:
    • H-23256
    First Posted:
    Jun 18, 2013
    Last Update Posted:
    Jun 18, 2013
    Last Verified:
    Jun 1, 2013
    Keywords provided by Michael Stitely, Adjunct Associate Professor, West Virginia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 18, 2013